pharmaphorum August 6, 2024
There’s a new source of funding for life science companies in town, providing credit as an alternative to other financing avenues such as venture capital.
Symbiotic Capital – which starts life with more than $600 million at its disposal, is an affiliate of Bellco Capital, an investment form set up by Arie Belldegrun, a biotech entrepreneur formerly chief executive of Kite Pharma and currently executive chairman of Allogene.
Belldegrun is serving as co-chairman of the new Los Angeles-based company alongside Russell Goldsmith, the former chairman and CEO of City National Bank. Josh Bradley, Bellco’s chief investment officer, is another co-founder.
The company describes itself as a first-of-its-kind provider of “credit partnerships” that will provide financing to “compelling life science companies...
Today's Sponsors
Today's Sponsor